HER2 Interactome Profiling Reveals MARCKS as a Candidate Marker Associated with Aggressive Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• HER2 is a key diagnostic marker and therapeutic target in breast cancer.
• HER2 signaling complexes are not fully characterized in clinical breast cancer tissues.
• Understanding HER2 interactions is crucial for targeted therapies.

Purpose of the Study:

• To identify HER2-interacting protein complexes in breast cancer specimens.
• To explore the utility of the RIME method for membrane protein interactome studies.
• To discover novel prognostic and diagnostic markers for breast cancer.

Main Methods:

• Application of Rapid Immunoprecipitation Mass Spectrometry of Endogenous Proteins (RIME) on HER2-positive breast cancer tissues.
• Verification of novel interactors using proximity ligation assay and immunohistochemistry.
• TCGA analysis to correlate gene expression with clinical data.

Main Results:

• Successfully identified multiple HER2 complex components in clinical specimens.
• Discovered MARCKS as a novel HER2-interacting partner.
• High MARCKS expression correlates with ER negativity and suggests prognostic potential in aggressive breast cancer.

Conclusions:

• RIME is effective for elucidating membrane protein interactomes in clinical tissues.
• MARCKS is a potential prognostic indicator for aggressive breast cancer subtypes.
• The RIME method has broad applicability for discovering novel clinical markers in various cancers.